| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/26/2011 | EP2277595A2 Compounds for immunopotentiation |
| 01/26/2011 | EP2277531A1 Treatment of cns damage |
| 01/26/2011 | EP2277526A1 Pharmaceutical composition with tetrahydroisohumulone |
| 01/26/2011 | EP2277521A1 Tamper-resitant oral opioid agonist formulations |
| 01/26/2011 | EP2277520A2 A pharmaceutical composition for angiotensin ii-mediated diseases |
| 01/26/2011 | EP2277519A2 Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure |
| 01/26/2011 | EP2277503A1 Effervescent compositions comprising bisphosphonates and methods related thereto |
| 01/26/2011 | EP2277394A1 Nutritional composition for the treatment of pressure ulcers |
| 01/26/2011 | EP2276763A1 Mtor inhibitor salt forms |
| 01/26/2011 | EP2276744A1 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof |
| 01/26/2011 | EP2276508A1 Delivery of lfa-1 antagonists to the gastrointestinal system |
| 01/26/2011 | EP2276505A1 Use of a substance for manufacturing of a medicament for treatment of common cold |
| 01/26/2011 | EP2276496A1 Therapeutic modulation of ocular surface lubrication |
| 01/26/2011 | EP2276491A1 New therapy of treatment of the irritable bowel syndrome. |
| 01/26/2011 | EP2276488A1 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| 01/26/2011 | EP2276473A1 Carbidopa/lipodopa gastroretentive drug delivery |
| 01/26/2011 | EP2276467A2 Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation |
| 01/26/2011 | EP1849795B1 1-substituted-7-( -d-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same |
| 01/26/2011 | EP1742645B1 Compressed pharmaceutical compositions comprising peg and electrolytes |
| 01/26/2011 | EP1539956B1 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 01/26/2011 | EP1404365B1 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 01/26/2011 | CN1918128B Fused ring 4-oxopyrimidine derivative |
| 01/26/2011 | CN1713888B Cream for treatment of skin injured by the sun |
| 01/26/2011 | CN101959542A Drug delivery system |
| 01/26/2011 | CN101959533A Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| 01/26/2011 | CN101959532A Pharmaceutical composition for transnasal administration |
| 01/26/2011 | CN101959531A Agent for enhancing corneal epithelial barrier function |
| 01/26/2011 | CN101959530A Prophylactic or therapeutic agent for diabetes or obesity |
| 01/26/2011 | CN101959516A Methods of treating by inhibiting with quinaxoline inhibitors of PI3K-alpha |
| 01/26/2011 | CN101959511A Trpa1 antagonists |
| 01/26/2011 | CN101959429A Agonists for antimicrobial peptide systems |
| 01/26/2011 | CN101955997A Compositions and method for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene |
| 01/26/2011 | CN101954084A Medicinal composition for treating mixed infection in livestock and poultry and preparation method thereof |
| 01/26/2011 | CN101954083A Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate |
| 01/26/2011 | CN101954082A Angiotensin-converting enzyme inhibitor-containing compound preparation for treating hypertension |
| 01/26/2011 | CN101954081A Using method for improving medicament effect of pollen pini |
| 01/26/2011 | CN101953853A Preparation method of purified and deleaded propolis powder and propolis product |
| 01/26/2011 | CN101953795A Drug delivery nanodevice, its preparation method and uses thereof |
| 01/26/2011 | CN101427994B Gemcitabine-containing anti-cancer medicine sustained-release injection |
| 01/26/2011 | CN101273981B Preparation and method for treating diabetes |
| 01/25/2011 | USRE42072 High transport rates of hormones delivered across cell membranes, facilitating more efficient delivery of drugs and diagnostic agents by using a viscous fluid comprising a polysaccharide a form of hydrogel, lipogel or sols; drug delivery to mucous membranes; gastrointesinal systems |
| 01/25/2011 | US7875728 Hydrazonopyrazole derivatives and their use as therapeutics |
| 01/25/2011 | US7875709 Nucleic acids encoding interleukin-18 mutants |
| 01/25/2011 | US7875651 Epicatechin for hypertension treatment |
| 01/25/2011 | US7875637 Benzimidazole derivative and use as a II receptor antagonist |
| 01/25/2011 | US7875590 using an injectable or implantable rod-shaped formulation for delivery of osteogenic proteins to treat osteoporotic and/or osteopenic bone; bone morphogenic proteins |
| 01/25/2011 | US7875585 Hematopoietic cell E-selectin / L-selectin ligand glycosylated CD44 polypeptide |
| 01/25/2011 | US7875342 Porous ceramic composite bone grafts |
| 01/25/2011 | US7875290 Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 01/25/2011 | US7875259 Generating prion specific immunoglobulin for use in diagnosis, prevention and treatment of neurodegenerative disorders |
| 01/25/2011 | CA2635963C Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 01/25/2011 | CA2483448C Anti-acne compositions and methods of use |
| 01/25/2011 | CA2483090C Use of therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions |
| 01/25/2011 | CA2476983C Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma |
| 01/25/2011 | CA2468681C Adenosine a2a receptor antagonists |
| 01/25/2011 | CA2468673C Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| 01/25/2011 | CA2468180C Anti-proliferative composition |
| 01/25/2011 | CA2454532C Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
| 01/25/2011 | CA2450962C Drug delivery devices |
| 01/25/2011 | CA2447765C 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 01/25/2011 | CA2441834C Lipid profile modulation |
| 01/25/2011 | CA2432582C Sulfamidothienopyrimidines |
| 01/25/2011 | CA2430857C Percutaneous absorption-type pharmaceutical preparation and process for producing the same |
| 01/25/2011 | CA2369175C Methods for stabilizing liquid nutritional products and products so stabilized |
| 01/25/2011 | CA2368849C Process for preparing amine platinum complexes |
| 01/25/2011 | CA2355768C Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| 01/25/2011 | CA2344467C Ucp4 |
| 01/20/2011 | WO2011009061A1 Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
| 01/20/2011 | WO2011009020A2 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| 01/20/2011 | WO2011009015A1 (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| 01/20/2011 | WO2011007801A1 Anti-cancer agent, method for inducing apoptosis of cancer cells, and method for screening for anti-cancer agent |
| 01/20/2011 | WO2011007565A1 PREVENTION AND TREATMENT OF ANEURYSMS USING PPARγ INHIBITOR |
| 01/20/2011 | WO2011007135A1 Use of pro-inflammatory compounds for promoting bone formation |
| 01/20/2011 | WO2011007102A1 Use of at least one omega-3 fatty acid and of at least one polyphenol for the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid |
| 01/20/2011 | WO2011006573A1 Combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative |
| 01/20/2011 | WO2010138600A3 Pharmaceutical compositions for the treatment of pain |
| 01/20/2011 | WO2009120889A3 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| 01/20/2011 | US20110016538 Susceptibility locus for schizophrenia |
| 01/20/2011 | US20110014301 Metal compounds, mixed or sulphated, as phosphate binders |
| 01/20/2011 | US20110014166 Probiotics Spore-forming Lactic Acid Bacteria SL153 |
| 01/20/2011 | US20110014123 RNA interference mediating small RNA molecules |
| 01/20/2011 | DE102009027744A1 Prekursor-Verbindungen von Süßrezeptor-Antagonisten zur Prävention oder Behandlung von Krankheiten Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of diseases |
| 01/20/2011 | CA2768356A1 Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
| 01/20/2011 | CA2768236A1 (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| 01/20/2011 | CA2768104A1 Combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative |
| 01/20/2011 | CA2768050A1 Use of at least one omega-3 fatty acid and of at least one polyphenol for the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid |
| 01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 01/19/2011 | EP2275450A1 Treatment with anti-ERBB2 antibodies |
| 01/19/2011 | EP2275449A1 Antibodies that immunospecifically bind to blys |
| 01/19/2011 | EP2275447A1 Methods of inhibiting metastasis |
| 01/19/2011 | EP2275446A2 Antibodies to insulin-like growth factor I receptor |
| 01/19/2011 | EP2275152A1 Calcium-containing structures and methods of making and using the same |
| 01/19/2011 | EP2275140A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 01/19/2011 | EP2275139A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
| 01/19/2011 | EP2275138A1 Promoter for bicarbonate secretion in gastrointestinal tract |
| 01/19/2011 | EP2275135A1 Therapeutic for hepatic cancer |
| 01/19/2011 | EP2275118A2 Pancreas-specific proteins |
| 01/19/2011 | EP2275115A2 Inhibition of stress-induced ligand-dependent EGFR activation |
| 01/19/2011 | EP2275109A2 Pregnane steroids for use in the treatment of CNS disorders |
| 01/19/2011 | EP2275108A1 Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form |